市场调查报告书
商品编码
1445530
全球导管相关血流感染(CRBSI)市场评估:按药物类别、治疗、来源、分销管道和地区划分的机会和预测(2017-2031年)Catheter-Related Bloodstream Infection Market Assessment, By Drug Class, By Treatment, By Source of Infection, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F |
全球导管相关血流感染 (CRBSI) 市场规模将从 2023 年的 17.1 亿美元增长到 2031 年的 25 亿美元,2024-2031 年预测期间复合年增长率为 5.35%。预计将增长到9000万美元。
市场成长的驱动因素是世界不同地区侵入性医疗程序数量的增加、人口老化的加剧、慢性病盛行率的增加。
越来越多地采用先进产品和技术(例如增强型诊断方法和抗菌涂层导管)来预防和治疗 CRBSI,为市场提供了利润丰厚的成长机会。 CRBSI 的长期挑战是推动尖端解决方案的开发。 不当的灭菌方法和不断增加的医院感染盛行率是推动市场需求的一些主要因素。 研究机构和主要参与者越来越关注开发促进患者安全的先进产品,这进一步支持了市场扩张。
增加与 CRBSI 相关的研究活动
正在进行各种研究活动和调查,以了解与这种疾病相关的各种併发症并追踪 CRBSI 并最终减少病例数。 2023年,在加纳一家三级医院进行的一项横断面研究发表,旨在确定维持性血液透析患者中□□与CRBSI相关的因素,观察到CRBSI的盛行率很高。
参与公司加强开发新疗法
各个主要参与者正在努力开发 CRBSI 的治疗和预防解决方案。 2023 年,CorMedix, Inc. 的 DefenCath 获得 FDA 批准。 这种含有肝素和牛磺罗定的导管封管溶液有助于治疗和预防接受中心静脉导管慢性血液透析的成人的 CRBSI。 DefenCath 是水性、无菌、透明且不含防腐剂的,是美国核准的第一个也是唯一一个抗菌封管液。
北美占较大市占率
该地区的市场扩张是由于老年人口的不断增长、导管插入术的需求不断增加、医疗基础设施的完善以及血液相关感染治疗技术的快速进步。 根据人口参考局的数据,从 2022 年到 2050 年,65 岁及以上的美国人数量预计将增加 47%。 预计这一数字将从5,800万人(2022年)增加到8,200万人(2050年),65岁及以上人口比例预计将从17%增加到23%。
本报告调查了全球导管相关血流感染(CRBSI) 市场,并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构和市场成长。它总结了影响因素的分析因素、案例研究、竞争格局和主要公司概况。
Global catheter-related bloodstream infection market is projected to witness a CAGR of 5.35% during the forecast period 2024-2031, growing from USD 1.71 billion in 2023 to USD 2.59 billion in 2031F. The market growth is driven by a rise in the number of invasive medical procedures, an increasing aging population, and a growing prevalence of chronic diseases in various regions across the globe.
The rising adoption of advanced products and technologies for the prevention and treatment of catheter-related bloodstream infections, including enhanced diagnostic methods and antimicrobial-coated catheters, is providing lucrative growth opportunities for the market. The long-posed challenges of catheter-related bloodstream infections are prompting the development of cutting-edge solutions. The increasing incidence related to improper aseptic procedures and the growing prevalence of hospital-acquired infections are some of the major factors bolstering the market demand. The increasing emphasis of research organizations and major market players on the development of advanced products that promote patient safety is further supporting the market expansion.
According to a ScienceDirect article, in the Elsevier Journal in December 2023, a team of researchers and The Flume Catheter Company, in the United Kingdom is working on the development and testing of a FLUME urinary catheter with relocated drainage holes and protected tip. The retaining balloon supports a static load of 700 grams and reduced trauma when forced evulsion was modeled. The catheter design aims to enhance patient safety and comfort while maximizing bladder drainage.
Increasing Research Activities on CRBSI
Various research activities and studies are being conducted to understand the different complications associated with the disease and track CRBSI to ultimately reduce the number of cases. In 2023, a cross-sectional study conducted at a tertiary hospital in Ghana to determine the factors associated with catheter-related bloodstream infections among patients who were on maintenance hemodialysis was published. The cross-sectional hospital-based study was conducted on patients who were receiving maintenance hemodialysis via central venous catheters. The risk factors that were predictive of catheter-related bloodstream infections were determined with the help of multivariate analysis using logistic regression. High prevalence of catheter-related bloodstream infections was noted among patients undergoing hemodialysis. The most common causative agent was Coagulase negative Staphylococci. As per the conclusion of the study, there is a high requirement for infection surveillance units in the renal unit for tracking catheter-related bloodstream infections and taking significant measures to reduce these infections. It was noted that the prevalence of catheter-related bloodstream infections among the participants was 34.2%. A contributing factor for the prevalence of CRBSI in the participants of the study may be the lack of utilization of antiseptic or antibiotic lock system.
Increasing Efforts Towards Development of Novel Treatments by Market Players
Various major market players are dedicated towards developing treatment and prevention solutions for catheter-related bloodstream infections. In 2023, CorMedix, Inc. received FDA approval for DefenCath. The heparin and taurolidine containing catheter lock solution aids in treating and preventing catheter-related bloodstream infections in adults undergoing chronic hemodialysis through a central venous catheter. The aqueous-based, sterile, clear, and preservative-free DefenCath is the first and only antimicrobial catheter lock solution approved in the United States. DefenCath will allow healthcare providers to reduce the risk of infections in patients suffering from underlying kidney failure. The approval of the product was based upon the findings from the Phase 3 LOCK-IT-100 clinical study. The multicentral, randomized, active control, double-blind trial analyzed the safety and efficacy of DefenCath in lowering the incidences of catheter-related bloodstream infections in patients undergoing chronic hemodialysis due to kidney failure.
North America Accounts for a Significant Market Share
The expansion of the market in the region can be attributed to the growth of the geriatric population, increased requirement for catheters insertion, presence of a well-established healthcare infrastructure and rapid technological advancements for treatment of blood related infections. According to the Population Reference Bureau, the number of Americans aging 65 years and older is estimated to witness a 47% increase from 2022 to 2050. The number is projected to increase from 58 million (in 2022) to 82 million (by 2050). The share of the 65-and-older age group is expected to increase from 17% to 23%.
Frequent catheterization is often required in the elderly if they are suffering from urinary retention, continence, cancer, and pressure ulcers, increasing the risk of catheter-related bloodstream infections. Long-term catheterization is preferred by various caretakers and healthcare professionals as it reduces their burden and allows them to focus on the other requirements of the patient. However, catheterization for long intervals of time can often lead to complications and cause catheter-related bloodstream infections.
Increasing Research Activities on Coagulase-Negative Staphylococcus Support Segment Growth
Undergoing research activities are expected to determine how to effectively manage catheter-related bloodstream infection caused by coagulase-negative staphylococcus. As per the clinical guidelines, the management of coagulase-negative staphylococcus causing catheter-related bloodstream infections requires antibiotic treatment for five to seven days along with catheter removal. According to an Antibiotics article published in May 2023, in National Library of Medicine, randomized clinical trials are being conducted with the aim to determine whether no administration of antibiotic therapy is effective and safe in low-risk episodes of catheter-related bloodstream infections caused by coagulase-negative staphylococcus. In the study, the patients suffering from CRBSI caused by coagulase-negative staphylococcus were randomized 1:1 after the withdrawal of catheter were opted to receive or not receive parenteral antibiotics that act against the isolated strain. The secondary endpoints of the study were septic embolism, persistent bacteremia, time until the disappearance of the fever, and time until microbiological cure. The primary endpoint was the occurrence of any complications related to the antibiotic therapy or bacteremia within the ninety days of the follow-up.
Online Pharmacies Expected to Witness Significant Growth Over the Forecast Period
Owing to the convenience offered by online pharmacies, including fast deliveries, this distribution channel has evolved from an alternative method for procuring medication and has gained immense popularity. Over the past few years more patients have recognized the convenient nature of shopping across these pharmacies, supplanting the reliance on retail pharmacies. According to a survey funded by Sanofi Consumer Healthcare, respondents indicated various advantages of online pharmacies including reduced costs for patients, convenience, and increased access for patients.
Online pharmacies eliminate the requirement of calling in a prescription, walking or driving to the pharmacy and waiting in line. The unparalleled levels of confidentiality and privacy offered by online pharmacies is further boosting the popularity of the distribution channel. The growth of the segment is facilitated by the rapid expansion of the internet services and ease of mail-order trade. Furthermore, the price transparency and accessibility offered by online pharmacies is encouraging consumers to adopt these channels for purchasing different medication.
Future Market Scenario (2024 - 2031F)
The catheter-related bloodstream infection (CRBSI) market is expected to witness significant growth in the coming years due to several factors including increasing emphasis on research and development activities and growing requirement for catheters in elderly patients.
The rising investments towards the healthcare and pharmaceutical industries is expected to offer lucrative growth opportunities to the market.
Various studies are being conducted to examine the risk of catheter-related bloodstream infections in patients with hemodialysis catheters. For instance, Zealand University Hospital is conducting an interventional study to examine the effects of ethanol (70%) as a lock solution. The study is estimated to conclude in April 2025.
University of Zurich is on the phase 4 of their interventional study aiming to understand the effect of vancomycin after catheter replacement. The randomized controlled trial will study the effect of a single dose of vancomycin on infection resolution after the replacement of catheter for suspected central line-associated bloodstream infection. The study is expected to conclude in December 2024.
Key Players Landscape and Outlook
Key participants in the catheter-related bloodstream infection market include Pfizer Inc., Citius Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., CorMedix, Inc., and Teva Pharmaceuticals. Increasing research and development activities and strategic partnerships between leading market players is expected to offer lucrative growth opportunities to the market.
In 2023, CorMedix, Inc. received FDA approval for DefenCath. According to FDA, the drug will reduce incidences of catheter-related bloodstream infections in adults receiving chronic hemodialysis via a central catheter due to kidney failure.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work